Emerging evidence of the impact of kidney disease on drug metabolism and transport

被引：205

作者：

Nolin, T. D. ^{[4
,5
]}

Naud, J. ^{[1
,2
,3
]}

Leblond, F. A. ^{[1
,2
]}

Pichette, V. ^{[1
,2
,3
]}

机构：

[1] Hop Maison Neuve Rosemont, Ctr Rech, Montreal, PQ H1T 2M4, Canada

[2] Hop Maison Neuve Rosemont, Serv Nephrol, Montreal, PQ H1T 2M4, Canada

[3] Univ Montreal, Dept Pharmacol, Montreal, PQ H3C 3J7, Canada

[4] Maine Med Ctr, Res Inst, Ctr Clin & Translat Res, Scarborough, ME USA

[5] Maine Med Ctr, Dept Med, Div Nephrol & Transplantat, Portland, ME 04102 USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2008年 / 83卷 / 06期

关键词：

D O I：

10.1038/clpt.2008.59

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Several lines of emerging evidence indicate that kidney disease differentially affects uptake and efflux transporters and metabolic enzymes in the liver and gastrointestinal (GI) tract, and uremic toxins have been implicated as the cause. In patients with kidney disease, even drugs that are eliminated by nonrenal transport and metabolism could lead to important unintended consequences if they are administered without dose adjustment for reduced renal function. This is particularly so in the case of drugs with narrow therapeutic windows and may translate into clinically significant variations in exposure and response.

引用

页码：898 / 903

页数：6

共 38 条

[11] Down-regulation of hepatic cytochrome P450 in chronic renal failure:: role of uremic mediators
Guévin, C
Michaud, J
Naud, J
Leblond, FA
Pichette, V
[J]. BRITISH JOURNAL OF PHARMACOLOGY, 2002, 137 (07) : 1039 - 1046
[12] Effect of hemodialysis on the metabolic clearance of 5-fluorouracil in a patient with end-stage renal failure
Gusella, M
Rebeschini, M
Cartei, G
Ferrazzi, E
Ferrari, M
Padrini, R
[J]. THERAPEUTIC DRUG MONITORING, 2005, 27 (06) : 816 - 818
[13] DISPOSITION OF ROXITHROMYCIN IN PATIENTS WITH NORMAL AND SEVERELY IMPAIRED RENAL-FUNCTION
HALSTENSON, CE
OPSAHL, JA
SCHWENK, MH
KOVARIK, JM
PURI, SK
HO, I
MATZKE, GR
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (03) : 385 - 389
[14] Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency
Haubitz, M
Bohnenstengel, F
Brunkhorst, R
Schwab, M
Hofmann, U
Busse, D
[J]. KIDNEY INTERNATIONAL, 2002, 61 (04) : 1495 - 1501
[15] KANFER A, 1987, CLIN NEPHROL, V27, P147
[16] KRIBY BJ, 2007, CLIN PHARMACOL THER, V81, P631
[17] In vitro and in vivo correlation of hepatic transporter effects on erythromycin metabolism: Characterizing the importance of transporter-enzyme interplay
Lam, Justine L.
Okochi, Hideaki
Huang, Yong
Benet, Leslie Z.
[J]. DRUG METABOLISM AND DISPOSITION, 2006, 34 (08) : 1336 - 1344
[18] Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers
Lau, Y. Y.
Huang, Y.
Frassetto, L.
Benet, L. Z.
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (02) : 194 - 204
[19] Leblond F, 2001, J AM SOC NEPHROL, V12, P326, DOI 10.1681/ASN.V122326
[20] Downregulation of intestinal cytochrome P450 in chronic renal failure
Leblond, FA
Petrucci, M
Dubé, P
Bernier, G
Bonnardeaux, A
Pichette, V
[J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 (06): : 1579 - 1585

← 1 2 3 4 →